MBX Biosciences, Inc. (MBX)
| Market Cap | 1.39B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -86.97M |
| Shares Out | 47.57M |
| EPS (ttm) | -2.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 809,692 |
| Open | 31.79 |
| Previous Close | 31.97 |
| Day's Range | 28.96 - 32.19 |
| 52-Week Range | 9.00 - 44.89 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 56.00 (+91.78%) |
| Earnings Date | May 7, 2026 |
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy fo... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for MBX stock is "Strong Buy." The 12-month stock price target is $56.0, which is an increase of 91.78% from the latest price.
News
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
CARMEL, Ind. and BURLINGTON, Mass.
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr...
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for o...
MBX Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference
The platform enables extended peptide therapies for endocrine and metabolic diseases, with phase III for once-weekly PTH therapy in hypoparathyroidism starting Q3 and a robust obesity pipeline advancing. Key differentiators include urine calcium endpoints and monthly dosing for obesity, with major data readouts expected in Q2 and Q4.
MBX Biosciences Transcript: The Citizens Life Sciences Conference 2026
FDA alignment for phase three in hypoparathyroidism keeps timelines on track, with strong phase two results and high physician interest in once-weekly dosing. Obesity pipeline advances with MBX 4291 and additional candidates, supported by robust funding into 2029.
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr...
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows.
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr...
MBX Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Significant progress was highlighted across endocrine and obesity programs, with phase III trials for canvorparotide set for Q3 and key obesity data expected in Q4. The proprietary PEP platform underpins a robust pipeline, strong financials, and multiple near-term catalysts.
MBX Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026 is set as a transformative year with major clinical milestones, including phase III initiation for canvuparatide and key obesity program readouts. Strong financials support pipeline expansion, with robust physician and patient enthusiasm for once-weekly therapies.
MBX Biosciences to Participate in Upcoming March Investor Conferences
CARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel pr...
MBX Biosciences to Participate in Upcoming Investor Conferences
CARMEL, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel pr...
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pre...
MBX Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
Multiple clinical milestones are set for 2024, including phase III initiation for canvuparatide and expansion of the obesity pipeline. The PEP platform's unique prodrug and fatty acylation technologies support less frequent, better-tolerated dosing, with strong patient and physician preference for weekly or monthly regimens.
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-we...
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ther...
MBX Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference
Strong Phase II data for once-weekly canvuparatide set up a global Phase III in Q3, with a new injector device and high patient enthusiasm. Pipeline includes a once-monthly GLP-1/GIP agonist for obesity and a post-bariatric hypoglycemia program, both with key data in 2026. Cash runway extends into 2029.
MBX Biosciences Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit
The summit highlighted a robust pipeline in endocrine and metabolic diseases, with MBX 4291 aiming for once-monthly obesity treatment and best-in-class tolerability. Canvuparatide's strong phase II results set up a pivotal phase III, while imapextide targets a major unmet need in post-bariatric hypoglycemia.
MBX Biosciences Transcript: Jefferies London Healthcare Conference 2025
The company is advancing three clinical-stage programs in endocrine and metabolic disorders, highlighted by strong phase II results for once-weekly canvuparatide and robust physician and patient support. Key catalysts are expected in 2026, with funding secured through 2029.
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference
CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ther...
MBX Biosciences Transcript: Stifel 2025 Healthcare Conference
Three clinical-stage programs are advancing in hypoparathyroidism, PBH, and obesity, with strong phase II data for Canvuparatide and a focus on once-weekly or monthly dosing. Physician and patient feedback supports category leadership ambitions, and multiple catalysts are expected through 2026.
MBX Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Three clinical-stage programs are advancing, with Canvuparatide showing strong phase II results and high patient retention, and MBX 4291 and Imipexatide targeting large unmet needs in obesity and PBH. Key catalysts are expected in 2026, with major data presentations planned.
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross p...
MBX Biosciences to Participate in November Investor Conferences
CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ther...